TLPH

Talphera, Inc. (NASDAQ:TLPH) is a specialty pharmaceutical company founded in 2005 and headquartered in San Mateo, California. Originally incorporated as AcelRx Pharmaceuticals, the company rebranded to Talphera in January 2024 following a strategic transformation. The company went public in 2011 and has evolved from developing pain management solutions to focusing exclusively on therapies for medically supervised settings, particularly critical care environments. Talphera divested its primary commercial asset, DSUVIA (a pain medication), in 2023 to concentrate resources on developing nafamostat-based anticoagulation therapies for hospital intensive care units.